Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference

Core Insights - Tivic Health Systems, Inc. is set to provide a corporate update on its immunotherapeutic candidate Entolimod during the Emerging Growth Virtual Conference on January 21-22, 2026, highlighting recent advancements in manufacturing readiness [1][2] Company Developments - The CEO, Jennifer Ernst, will discuss the scale-up validation for Entolimod manufacturing and the vertical integration of Velocity Bioworks, which enhances in-house manufacturing capabilities and introduces new revenue streams [1] - The acquisition of Velocity Bioworks is expected to lower production costs, eliminate outsourcing delays, and accelerate the validation of current Good Manufacturing Practice (cGMP) for Entolimod [1] Product Information - Entolimod is a novel Toll-like Receptor 5 (TLR5) agonist that activates the NF-kappaB pathway, showing promising results in animal trials for Acute Radiation Syndrome (ARS), including improved survival rates and gastrointestinal recovery [5][6] - The drug is in late-stage development and aims to prevent cell death in bone marrow and epithelial tissues affected by radiation and age [6] Conference Details - The Emerging Growth Virtual Conference serves as a platform for public companies to present their innovations and major announcements to a broad audience of investors and analysts [3][4]